The results indicate that NT4 peptides are a promising new selective tumor-targeting theranostic for human bladder cancer and may enable personalized oncology in which cancer diagnosis and therapy are obtained by means of the same molecule, with no modification in target binding but by simply “exchanging” the functional units. The gene discussed is NTF4; the disease is urinary bladder carcinoma.